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hybridised against female human genomic DNA to a high resolution 
array-Comparative Genomic Hybridisation (aCGH) platform contain-
ing ~43,000 probes (Agilent 44K Human Whole-Genome 44B arrays). 
Genomic regions with signiﬁcant copy-number variation (CNV) (DNA 
gain/loss) were identiﬁed using an aberration detection algorithm (CGH 
Analytics V3.4).
Results: The most frequent CNVs in current smokers were gain 
of 1q21.1-q24.2 and 5p15.33-p12 (>60% of tumours) and loss of 
8p23.3-p12 and 13q12.11-q34 (>20% of tumours). The most frequent 
CNVs in former smokers were gain at 1q25.2-q44 and 17q11.2-q25.3 
(>50% of tumours) and loss at 13q12.11-q21.2 and 21q11.2-q22.3 
(>20% of tumours). The most frequent CNVs in never smokers were 
gain at 7p22.3-p11.2 (>50% of tumours) and loss at 8p23.3-p11.22 
and 13q13.3-q14.3 (>50% of tumours). CNVs present in both current 
and former smokers were compared to identify recurrent (occurring in 
>30% of tumours, both smokers and former smokers) genomic aber-
rations. Frequent copy-number gain was observed at 1q21.1-q31.3, 
1q31.1-q44, 3q26.1-q29, 5p15.33-p12, 7p22.1-p11.2, 7p11.1-q36.2, 
and 17q21.2-q25.3. Gain at 1q25.2-q31.3 occurred in more than 50% 
of current and former smokers, yet was rarely gained in never-smokers 
(8%).
Conclusions: In the chaos that occurs in lung cancer cells that develop 
in current smokers (with continued carcinogenic exposure and therefore 
high lung cancer risk), those aberrations in common with lung cancer 
cells that develop in former smokers (with no further carcinogenic 
exposure and therefore lower but persistent lung cancer risk) may 
represent irreversible causative genetic damage. Genes located in these 
aberrations represent strong chemoprevention targets. Our analysis has 
identiﬁed several loci frequently aberrant in both current and former 
smokers. These loci are now being further studied to identify the poten-
tial gene targets of aberration.
Funding: IASLC Lung Cancer Fellowship, NHMRC (338602, 338200), 
TPCH (FRC0205-23).
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Objective: The Danish lung cancer screening trial is a randomized trial 
comparing CT screening with no screening. The trial is done with the 
NELSON trial in the Netherlands, Europe. The ﬁnal end point is lung 
cancer mortality.
Methods: From 2004 to 2006 4104 Danish smokers and previous 
smokers were randomized to either screening with annual low dose CT 
scans for 5 years or no screening. A history of cigarette smoking of at 
least 20 pack years was required. All had lung function tests, and ques-
tionnaires regarding psychosocial consequences of screening, smoking 
and smoking cessation at randomization and planned annually. 
All scans are performed with a 16 detector row CT scanner at low dose 
levels, and viewed independently by two board certiﬁed radiologists. 
Nodules identiﬁed in the baseline year were considered prevalence 
nodules. 
Nodules were classiﬁed according to size and other characteristic: 
• Nodules smaller than 5 mm and calciﬁed nodules with a maximal 
diameter up to 20 mm were just tabulated. 
• Uncalciﬁed nodules with a diameter between 5 and 15 mm were 
re-scanned after 3 months; 1) if the size was stable or reduced no 
further action was taken.2) If the nodule grew it was referred for 
invasive workup, as were uncalciﬁed nodules larger than 15 mm.
CT with contrast and PET CT was performed before any invasive 
procedures. 
Results: At baseline 177 persons had nodules larger than 5 mm on the 
ﬁrst scan, and almost all were rescanned after 3 months. 
• Seventeen individuals (0.8%) with a suspicious lung nodule were 
referred to surgical exploration and all turned out to have cancer. 
One stage IA patient had segmental resection (adenocarcinoma 
(ACL) dominated by BAC features), ten patients (6 stage IA, 3 stage 
IB and 1 stage IIIB) had lobectomy (9 ACL and 1 squamous cell 
carcinoma (SQC), one stage IIIA had pneumonectomy (ACL).The 
remaining ﬁve patients were in stage IIIA after diagnostic evaluation 
and received chemotherapy (3 non small cell lung carcer (NSCLC), 
probably ACL, 1 ACL, 1 SQC). 
• Seventy one percent had ACL, 12% SQC and 17% NSCLC. No 
SCLC was diagnosed.
• Twelve of 17 lung cancers at base line were treated surgically, 8 of 
these were treated by VATS resection.
• One participant had a benign hamartoma (4 cm) removed by VATS 
local resection and one had a diagnostic VATS on suspicion of me-
sothelioma which turned out to be pleural tuberculosis.
• Rate of false positive diagnoses was 8,6 %. 
• In the control group so far one patient had a lobectomy (ACL) stage 
1, one had a pneumonectomy for a stage IIIA lung cancer, two had 
oncological treatment for stage 4 disease (ACL) and one patient died 
with lung cancer stage IIIB (ACL). 
Conclusion: Screening facilitates minimal invasive treatment and can 
be performed with a low rate of false positive diagnoses. 
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Background: Caspase-3 (CASP-3) is a primary effector CASP that 
executes programmed cell death, and it plays an important role in the 
development and progression of cancer. Polymorphisms in the CASP-
3 gene may inﬂuence CASP-3 production and/or activity, thereby 
modulating the susceptibility to lung cancer. To test this hypothesis, we 
investigated the association between CASP-3 polymorphisms and the 
risk of lung cancer in a Korean population. 
Methods: We ﬁrst screened single nucleotide polymorphisms (SNPs) 
in the CASP-3 gene by direct sequencing of genomic DNA samples 
taken from 27 healthy Korean individuals. We selected identiﬁed SNPs 
based on their frequency, linkage disequilibrium (LD) status and haplo-
type tagging status, and then genotyped the selected SNPs in 582 lung 
cancer patients and 582 healthy controls who were frequency matched 
for age and gender. 
Results: We identiﬁed eight SNPs: six known SNPs (-928A>G, 
246C>T, 829C>A, 1143G>C, 17532A>C and 20541C>T); and two 
novel SNPs (77G>A and 163G>T). Individuals with at least one variant 
allele of the -928A>G, 77G>A and 17532A>C polymorphisms were at 
a signiﬁcantly decreased risk for lung cancer in comparison to the carri-
ers with each homozygous wild-type allele [adjusted odds ratio (OR) = 
0.79, 95% conﬁdence interval (CI) = 0.62-1.00, P = 0.05; adjusted OR 
= 0.78, 95% CI = 0.61-0.99, P = 0.04; and adjusted OR = 0.74, 95% 
CI = 0.58-0.95, P = 0.02, respectively). Consistent with the results of 
genotyping analysis, the GAGC haplotype carrying the variant allele at 
all of the -928A>G, 77G>A, and 17532A>C loci was associated with a 
signiﬁcantly decreased risk of lung cancer compared to the AGGA hap-
lotype carrying no variant alleles at the three loci (adjusted OR = 0.66, 
95% CI = 0.51-0.86, P = 0.002 and Bonferroni corrected P = 0.008). 
Conclusions: These results suggest that the CASP-3 polymorphisms 
and their haplotypes contribute to the genetic susceptibility to lung 
cancer.
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Background: Improved early detection remains the most promising 
method of improving patient survival from lung cancer, and is a realis-
tic goal in the short term. This study reports the ﬁndings of a large scale 
trial evaluating a novel, fully automated method of DNA cytometry on 
sputum to detect lung cancer.
Methods: Over a period of 18 months, 1235 patients clinically suspi-
cious of having lung cancer were recruited into a multinational valida-
tion trial of the LungSign™ sputum test. Induced sputum was collected 
at the time of initial presentation, ﬁxed and treated with dithiothreitol 
(DTT). Papanicolaou stained smears were prepared and analysed by 
conventional cytology. Monolayer cytospin slides were prepared and 
stained using the Feulgen-thionin method. Cytospin slides were scored 
using LungSign, a test that uses a fully automated computerised DNA 
cytometry system to analyze thousands of epithelial cell nuclei to gen-
erate a measure associated with malignancy.
Results: Of the 1123 patients analysed, 370 proved to have lung cancer 
(prevalence 33%). The LungSign test provided an ROC “area under 
the curve” value of 0.692, and for a speciﬁcity of 91% it detected 40% 
of all lung cancers (Figure 1). Results were similar for all lung cancer 
histological types, as well as early (up to 1b) and later (stage 2a and 
above) stages. Conventional cytology detected 16% of cancers with a 
speciﬁcity of 99%. Approximately 12% of cytospins contained insuf-
ﬁcient epithelial cells for cytometric analysis. The inadequacy rate for 
conventional cytology was 43%.
Conclusions: In a high risk population, the LungSign test provides an 
effective means of detecting those patients most likely to have lung 
cancer. It is a continuous measure, permitting different cut points to be 
set. This ﬂexibility allows the test to be used in multiple contexts such 
as screening patients for lung cancer or evaluating suspicious lesions 
detected on CT, thereby directing efﬁcient use of other, more expensive 
and invasive diagnostic modalities.
Figure 1; ROC curve for the LungSign score, with conventional cytology 
(circle). Sensitivity and specificity standard error bars representing one stan-
dard deviation are shown.
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Background: Pre-clinical studies have shown that the majority of 
NSCLC have decreased expression of prostacyclin synthase (PGIS) and 
genetically modiﬁed mice with selective pulmonary PGIS overexpres-
sion are chemoprevented from developing lung cancer in a variety of 
models, including cigarette smoke exposure. Based on these promising 
results, a multi-center, double-blind, placebo controlled, phase II trial 
of iloprost (an oral prostacyclin analogue) in subjects at increased risk 
for lung cancer was initiated and continues to enroll.
Methods: Subjects are selected for the trial if they meet the follow-
ing criteria: current or former smoker (> 20 pack years); at least mild 
cytologic atypia on sputum cytology; no previous history of cancer. 
Fluorescent bronchoscopy is then performed with 6 standard sites biop-
sied, along with all other abnormally appearing areas. Subjects are then 
randomized to iloprost (in escalating doses) or placebo for 6 months 
and then undergo a repeat ﬂuorescent bronchoscopy with repeat biopsy 
of all the central airway areas sampled on the ﬁrst bronchoscopy. The 
primary endpoints for the study are bronchial histology and Ki-67 
